95 results
Page 4 of 5
8-K
EX-99.1
n3ncl9mt8b
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
ahha s66brh5wbmeve
15 Jun 20
Regulation FD Disclosure
7:21am
8-K
EX-1.1
vjnnljq icz
12 May 20
Entry into a Material Definitive Agreement
5:14pm
424B5
3dch10q
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
2ol cwwsh2txq
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
ej4wmxb kl5rzsf7b
11 May 20
Prospectus supplement for primary offering
4:12pm
8-K
u5c249a uizb32n
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
br1znv2tkqmh e1fnv94
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.2
62i713hgb0l5mnrvl0q
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
j7j8ogxj89c 6jzad
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
sttdd1eg mszh5ya
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
b3674v
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
EX-99.1
c682cm8wj5jz
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
EX-99.2
3kjmdym0aa6an9rdvqka
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
424B5
l1arllc1dlfpq
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
8bkztekiwu xck
4 Oct 19
Shelf registration
4:06pm